In The News
The ASCO Post

Researchers Find Evidence-Based Radiation Treatment After Lumpectomy Leads to High-Quality, High-Value Care


Researchers Discover Key to Drug Resistance in Common Breast Cancer Treatment


Age and Subtype Impact Outcomes More Than Surgical Extent in Breast Cancer


Neoadjuvant Therapy Fundamental in Triple-Negative and HER2-Positive Breast Cancer

Kisqali Approved by FDA to Treat Hormone-Receptor-Positive, Advanced-Stage Disease

In Patients With Diabetes, Metformin is Linked to Improved Outcomes in Patients With HER2-Positive, Hormone-Receptor-Positive Breast Cancer

Cancer Network

HER2 Guidelines for Breast Cancer Could Misclassify Some Patients

Cure Today

Neoadjuvant Treatment Options May Improve Chances of Breast Conservation

The ASCO Post

Veliparib Improves Reponse but Not Progression-Free Survival in BRCA-Mutation Carriers


Women Who Have a False-Positive Screening Mammogram Are More Likely to Delay Their Next Screening


Genetic Testing Not Offered Enough to Breast Cancer Patients


Olaparib Improves PFS in Phase III BRCA-Positive/HER2-Negative Breast Cancer Trial


Breast Density Surpasses Other Risk Factors in Development of Breast Cancer


Women With Menopausal Symptoms More Likely to Stop Preventive Therapy

Breast Cancer Treatment Causes Severe Side Effects in Many Women

Women Treated for DCIS Live Longer Than Women With No History of DCIS

Neoadjuvant Abemaciclib Active in HER2-Positive/HR-Negative Breast Cancer

The ASCO Post

BRCA Status Does Not Seem to Affect Survival Outcomes in Young Women With Early Breast Cancer

Targeted Oncology

Nab-Paclitaxel Shows Greater Benefit Than Paclitaxel in Breast Cancer Subsets

Cancer Network

Increased TIL Levels Associated With Better Outcomes in Patients With HER2-Positive Breast Cancer

In HER2-Negative Breast Cancer, Brain Mets Are HER2-Positive 20% of the Time

Practice Update

Vinorelbine With Pertuzumab and Trastuzumab as First-Line Treatment in Patients With HER2-Positive Breast Cancer

Prophylactic Treatment Reduces Neratinib-Related Toxicity in HER2-Positive Breast Cancer

News Medical Net

HER2-Targeted Dendritic Cell Vaccine Shows Promise for Treating Patients with Early-Stage Breast Cancer

T-DM1 Offers Similar PFS, More Tolerable in Advanced HER2-Positive Breast Cancer


Innovative Drug May Revolutionize the Treatment of Early-Stage Breast Cancer

Science Daily

Rare HER2 Mutations May Not Always Spur Breast Cancers on Their Own


Higher Vitamin D Levels Associated with Better Outcomes in Breast Cancer Survivors

Elevated Troponin Levels Associated with Trastuzumab-Related Cardiac Dysfunction

Breast Cancer News

One-Third of People Diagnosed With Breast Cancer Not Getting Appropriate Follow-Up Imaging

MedPage Today

Benefits of Bone-Modifying Agents Confirmed in Breast Cancer

Science Daily

New Standard Helps Ensure Accurate Clinical Measurements of HER2 Breast Cancer Gene


Breast Cancer Cells Found to Switch Molecular Characteristics

MedPage Today

Breast Cancer: Ovarian Suppression Benefits High-Risk Premenopausal Patients

Medical News Today

Study Demonstrates How Breast Cancers Use White Blood Cells to Avoid Immune Defenses and Promote Growth

Science Daily

Updated Testing Guidelines Make More Women Eligible for Herceptin, Yet Benefit Uncertain

Oncology Nursing Forum

The Nurse Practitioner Role in Oncology: Advancing Patient Care

Breast Cancer.Org

Anthracycline Chemo Regimen Seems Better Than Regimen Without Anthracycline for Early-Stage, HER2-Negative, High-Risk Disease

The ASCO Post

Results of Two Pivotal Breast Cancer Trials Confirmed the Practice-Changing Findings that Resulted from Earlier Findings

The ASCO Post

Meta-analysis Indicates Similar Outcomes With Neoadjuvant Endocrine vs Chemotherapy in Estrogen Receptor–Positive Breast Cancer

Oncology Nurse Advisor

New Drug Combination Before Surgery May Improve Outcomes for Advanced HER2+ Breast Cancer


New Breast Cancer Staging System Emphasizes Importance of Tumor Biology as Prognostic Indicator

The ASCO Post

Hope S. Rugo, MD, on HER2+ Breast Cancer: Findings on a Trastuzumab Biosimilar


Best Surgery for Early-Stage Disease May Depend on Age

The ASCO Post

Meta-Aanalysis of Breast Cancer Studies Demonstrates Value of Pathologic Complete Response

The ASCO Post

Young Women Require Formal Assessment to Identify Breast Cancer Risk

Oncology Nurse Advisor

Presurgical Treatment in HER2-Positive Breast Cancer Achieves Significant Reduction in Disease

Cancer Research

SABCS Abstract OT3-01-04: An Open-Label, Single-Arm, Phase II Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Central Nervous System Progression Post-Radiotherapy in Patients With HER2-Positive Metastatic Breast Cancer (PATRICIA)

Cancer Therapy Advisor

Plenary Lecture at SABCS: Researchers Continue to Explore HER2 Blockade Strategies

The ASCO Post

Ado-Trastuzumab Emtansine Improved Overall Survival for Heavily Pretreated Patients With HER2-Positive Breast Cancer

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.